Key result
Circulating ANGPTL8 concentrations were significantly higher in PCOS women with metabolic syndrome, yielding an AUC of 0.87 (P<0.001) for detecting the condition.
Why the study?
ANGPTL8 regulates lipid metabolism and is linked to insulin resistance and metabolic syndrome, but whether it plays a role in metabolic syndrome in women with PCOS was unknown.
Is circulating ANGPTL8 associated with metabolic syndrome and insulin resistance in young women with PCOS?
Observational
Is circulating ANGPTL8 associated with metabolic syndrome and insulin resistance in young women with PCOS?
Effect estimate: AUC 0.87
p-value: p=<0.001
Circulating ANGPTL8 is elevated in PCOS patients with metabolic syndrome and may serve as a biomarker for the severity of metabolic disorders.
ANGPTL8 may mark metabolic syndrome in PCOS; hypothesis-generating and requires prospective validation before clinical use.
Background. ANGPTL8 has been reported to be a regulator of lipid metabolism, and it is associated with insulin resistance (IR) and metabolic syndrome (MetS). We investigated whether ANGPTL8 plays a role in MetS. Methods. ANGPTL8 and adiponectin concentrations were measured in PCOS patients with or without MetS and in their corresponding healthy controls. The association of circulating ANGPTL8 with adiponectin and other parameters was also examined. Results. Circulating ANGPTL8 concentrations were higher in PCOS women with MetS than in those without MetS and in the controls ( P<0.01 ). ANGPTL8 was positively correlated with age, BMI, FAT%, WHR, SBP, TG, FBG, HbA1c, Fins, and HOMA-IR (all P<0.01 ) in the study populations and negatively associated with adiponectin and M -values ( P<0.001 ). In addition, ANGPTL8 was positively correlated with PRL, LH, TEST, and FAI and negatively correlated with SHBG (all P<0.01 ). ROC curve analyses showed that the AUCMetS was 0.87 ( P<0.001 ), with a sensitivity of 92.4% and specificity of 75.4%, and the AUCIR was 0.82 ( P<0.01 ), with a sensitivity of 76.4% and specificity of 75.6%. Conclusion. ANGPTL8 levels progressively decrease from PCOS patients with MetS to those without MetS and may be a serum marker associated with the degree of metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Pu et al. (2019) conducted an observational in Polycystic Ovary Syndrome (PCOS) and Metabolic Syndrome (MetS). Circulating ANGPTL8 vs. Healthy controls and PCOS patients without MetS was evaluated on Presence of Metabolic Syndrome (MetS) (AUC 0.87, p=<0.001). Circulating ANGPTL8 concentrations were significantly higher in PCOS women with metabolic syndrome, yielding an AUC of 0.87 (P<0.001) for detecting the condition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: